Clinical Trial Update: Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin. [Phase 4]

View source ↗

Summary

Phase IV study evaluating the efficacy and safety of adding dapagliflozin to insulin therapy in Japanese patients with Type 2 Diabetes Mellitus who have inadequ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2016-03-17